Corcept Therapeutics Incorporated (NASDAQ:CORT) insider Robert S. Fishman sold 8,000 shares of the stock in a transaction dated Wednesday, November 7th. The stock was sold at an average price of $13.74, for a total transaction of $109,920.00. Following the sale, the insider now owns 8,000 shares in the company, valued at $109,920. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Corcept Therapeutics stock traded down $0.37 during trading hours on Friday, reaching $13.01. 1,231,630 shares of the stock were exchanged, compared to its average volume of 1,269,341. The company has a market capitalization of $1.60 billion, a price-to-earnings ratio of 29.57 and a beta of 1.80. Corcept Therapeutics Incorporated has a twelve month low of $11.21 and a twelve month high of $25.96.
Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Thursday, November 1st. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.16 by ($0.02). Corcept Therapeutics had a return on equity of 32.96% and a net margin of 63.79%. The firm had revenue of $64.45 million for the quarter, compared to analyst estimates of $67.42 million. During the same quarter in the previous year, the company earned $0.10 earnings per share. The company’s quarterly revenue was up 50.7% on a year-over-year basis. On average, research analysts forecast that Corcept Therapeutics Incorporated will post 0.6 earnings per share for the current year.
A number of brokerages have issued reports on CORT. BidaskClub upgraded shares of Corcept Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday. Cantor Fitzgerald reiterated a “hold” rating and set a $17.00 price objective on shares of Corcept Therapeutics in a research note on Friday, November 2nd. Zacks Investment Research upgraded shares of Corcept Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, October 10th. Finally, ValuEngine downgraded shares of Corcept Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, September 5th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company’s stock. Corcept Therapeutics presently has an average rating of “Hold” and a consensus price target of $21.83.
WARNING: This piece of content was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international copyright laws. The original version of this piece of content can be read at https://sportsperspectives.com/2018/11/10/corcept-therapeutics-incorporated-cort-insider-sells-109920-00-in-stock.html.
Corcept Therapeutics Company Profile
Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery, as well as develops CLIA-validated assay to measure FKBP5 gene expression.
Featured Story: The risks of owning bonds
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.